Clinical Trial Update: 1 Year of Treatment With Canakinumab in Behçet's Disease Patients With Neurologic or Vascular Involvement [Phase 2]

View source ↗

Summary

Phase 2 trial update reporting 1 year of.canakinumab treatment in Behçet's disease patients with neurologic or vascular involvement; study completed with result…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Behçet Disease

Drugs mentioned

• Canakinumab (canakinumab)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Behcet Disease | Phase 2 | Status: COMPLETED | Results posted: 2020-06-11